Prostacyclin for ischemic ulcers in peripheral arterial disease. A random assignment, placebo controlled study

Area of Science:

• Vascular Surgery
• Wound Healing
• Pharmacology

Background:

• Peripheral arterial disease (PAD) frequently causes ischemic ulcers, leading to significant morbidity.
• Current treatments for ischemic ulcers in PAD patients have limited efficacy, especially in non-diabetic individuals without gangrene.

Purpose of the Study:

• To evaluate the efficacy of intra-arterial prostacyclin infusion in promoting the healing of ischemic ulcers in patients with peripheral arterial disease.

Main Methods:

• A randomized, placebo-controlled study involving 30 patients with peripheral arterial disease and ischemic ulcers.
• Patients received a 72-hour intra-arterial infusion of either prostacyclin or a placebo into the femoral artery.
• Ulcer area was assessed six weeks post-infusion.

Main Results:

• A significant reduction in mean ulcer area was observed in the prostacyclin-treated group (p < 0.02).
• No significant change in ulcer area was noted in the placebo group (p > 0.05).
• Significant differences in ulcer area reduction were found between the prostacyclin and placebo groups (p < 0.02).

Conclusions:

• Intra-arterial prostacyclin infusion is an effective treatment for promoting the healing of ischemic ulcers.
• This therapeutic approach shows promise for non-diabetic patients with peripheral arterial disease who do not have gangrene.